Arkolith/Insider Trading/ARQT/Form 4

Watanabe Todd

See Remarks, DirectorArcutis Biotherapeutics, Inc. (ARQT) · full profile →Form 4 · filed Nov 24, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.5M
Net Open-Market Flow
-$1.5M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 24, 2025Sell(S)49K$30.36$1.5M741K
Nov 21, 2025Sell(S)1K$30.00$32K794K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001801061-25-000012) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML